Kyverna Therapeutics Inc (KYTX) Stock AnalysisKYTXStock AnalysisKyverna Therapeutics Inc

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

Kyverna Therapeutics Inc is a good buy right now due to its potential for significant growth driven by the upcoming launch of miv-cel for Stiff-Person Syndrome, which analysts estimate could generate peak sales of $800 million. The current price of $8.37 is well below the analyst price targets of $25 and $29, indicating substantial upside potential. However, the company has reported consistent net losses, with a net income of -$39.7 million in Q1 2026, which poses a risk to investors.